The clinical importance of acquired abnormalities of platelet function

New England Journal of Medicine

Volumn 324, Issue 1, 1991, Pages 27-39

  George, James N ^a   Shattil, Sanford J ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA LACTAM; CARDIOVASCULAR AGENT; CONTRAST MEDIUM; DESMOPRESSIN; NARCOTIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; TICLOPIDINE;

BLEEDING; CARDIOPULMONARY BYPASS; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 0025962624     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199101033240106     Document Type: Review

References (215)

1. Kroll M.H., Schafer A.I. Biochemical mechanisms of platelet activation. Blood 1989; 74:1181-1195
2. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69:58-178.
3. Lapetina E.G. The signal transduction induced by thrombin in human platelets. FEBS Lett 1990; 268:400-404
4. Brass L.F., Manning D.R., Shattil S.J. GTP-binding proteins and platelet activation. Prog Hemost Thromb 1990; 10:127-174
5. Ginsberg M.H., Loftus J., Plow E.F. Platelets and the adhesion receptor superfamily. In: Jamieson GA, ed. Platelet membrane receptors: molecular biology, immunology, biochemistry, and pathology: proceedings of the 19th Annual Scientific Symposium of the American Red Cross held in Washington, D.C. October 22–27, 1987. Vol. 283 of Progress in clinical and biological research. New York: Alan R. Liss, 1988: 171-95.
6. George J.N., Nurden A.T., Phillips D.R. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984; 311:1084-1098
7. Nieuwenhuis H.K., Sakariassen K.S., Houdijk W.P.M., Nievelstein P.F.E.M., Sixma J.J. Deficiency of platelet membrane glycoprotein la associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68:692-695
8. Hamburger S.A., McEver R.P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75:550-554
9. Larsen E., Celi A., Gilbert G.E., et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59:305-312
10. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.J., Shattil S.J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane: studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264:17049-57.
11. Comfurius P., Senden J.M.G., Tilly R.H.J., Schreit A.J., Bevers E.M., Zwaal R.F.A. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026:153-160
12. Mann K.G., Nesheim M.E., Church W.R., Haley P., Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76:1-16.
13. George J.N., Caen J.P., Nurden A.T. Glanzmann#x0027;s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75:1383-1395
14. Miller C.H., Graham J.B., Goldin L.R., Elston R.C. Genetics of classic von Willebrand#x0027;s disease. I. Phenotypic variation within families. Blood 1979; 54:117-126
15. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand#x0027;s disease. Blood 1987; 69:454-459
16. Abildgaard C.F., Suzuki Z., Harrison J., Jefcoat K., Zimmerman T.S. Serial studies in von Willebrand#x0027;s disease: variability versus “variants.” Blood 1980; 56:712-716
17. Ginsberg M.H., Frelinger A.L. III, Lam S.C.T., McMillan R., Plow E.F., Shattil S.J. Pathophysiological approach to platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb–IIIa. Blood 1990; 76:2017-2023
18. Charo I.F., Feinman R.D., Detwiler T.C. Interrelations of platelet aggregation and secretion. J Clin Invest 1977; 60:866-873
19. Coller B.S. Platelet aggregation by ADP, collagen and ristocetin: a critical review of methodology and analysis. In: Schmidt RM, ed. CRC Handbook series in clinical laboratory sciences. Section 1: Hematology. Boca Raton. Fla: CRC Press, 1979: 381-96.
20. Tiffany M.L. Technical considerations for platelet aggregation and related problems. CRC Crit Rev Clin Lab Sci 1983; 19:27-69.
21. Larsson P.T., Hjemdahl P., Olsson G., Angelin B., Hornstra G. Platelet aggregability in humans: contrasting in vivo and in vitro findings during sympatho-adrenal activation and relationship to serum lipids. Eur J Clin Invest 1990; 20:398-405.
22. Nieuwenhuis H.K., Akkerman J.W.N., Sixma J.J. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred and six patients. Blood 1987; 70:620-623
23. Israels S.J., McNicol A., Robertson C., Gerrard J.M. Platelet storage pool deficiency: diagnosis in patients with prolonged bleeding times and normal platelet aggregation. Br J Haematol 1990; 75:118-121
24. Mielke C.H. Jr., Kaneshiro M.M., Maher I.A., Weiner J.M., Rapaport S.I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34:204-215
25. Mielke C.H. Jr. Aspirin prolongation of the template bleeding time: influence of venostasis and direction of incision. Blood 1982; 60:1139-1142
26. Rodgers R.P.C., Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16:1-20.
27. Czapek E.E., Deykin D., Salzman E.W., Lian E.C., Hellerstein L.J., Rosoff C.B. Intermediate syndrome of platelet dysfunction. Blood 1978; 52:103-113
28. Stuart M.J., Miller M.L., Davey F.R., Wolk J.A. The post-aspirin bleeding time: a screening test for evaluating hemostatic disorders. Br J Haematol 1979; 43:649-659
29. Fiore L.D., Brophy M.T., Lopez A., Janson P., Deykin D. The bleeding time response to aspirin: identifying the hyperresponder. Am J Clin Pathol 1990; 94:292-296
30. Heiden D., Mielke C.H. Jr., Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol 1977; 36:427-436
31. Eyster M.E., Gordon R.A., Ballard J.O. The bleeding time is longer than normal in hemophilia. Blood 1981; 58:719-723
32. Rosing J., van Rijn J.L.M.L., Bevers E.M., van Dieijen G., Comfurius P., Zwaal R.F.A. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65:319-332
33. Hellem A.J., Borchgrevink C.F., Ames S.B. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961; 7:42-50.
34. Santos M.T., Valles J., Marcus A.J., et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest (in press).
35. O#x0027;Laughlin J.C., Hoftiezer J.W., Mahoney J.P., Ivey K.J. Does aspirin prolong bleeding from gastric biopsies in man? Gastrointest Endose 1981; 27:1-5.
36. O#x0027;Brien J.R. Effect of anti-inflammatory agents on platelets. Lancet 1968; 1:894-895
37. Maguire E.D., Pay G.F., Turney J., et al. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man. Haemostasis 1981; 10:153-164
38. McQueen E.G., Facoory B., Faed J.M. Non-steroidal anti-inflammatory drugs and platelet function. N Z Med J 1986; 99:358-360
39. Mielke C.H. Jr., Heiden D., Amadio P. Tolmetin: hematological effects in normal subjects. In: Ward JR, ed. Tolmetin: a new non-steroidal anti-inflammatory agent. Amsterdam: Excerpta Medica, 1976: 200-8.
40. Mielke C.H. Jr., Kahn S.B., Muschek L.D., Tighe J.J., Ng K.T., Minn F.L. Effects of zomepirac on hemostasis in healthy adults and on platelet function in vitro. J Clin Pharmacol 1980; 20:409-417
41. Buchanan G.R., Martin V., Levine P.H., Scoon K., Handin R.I. The effects of “anti-platelet” drugs on bleeding time and platelet aggregation in normal human subjects. Am J Clin Pathol 1977; 68:355-359
42. Nadell J., Bruno J., Varady J., Segre E.J. Effect of naproxen and of aspirin on bleeding time and platelet aggregation. J Clin Pharmacol 1974; 14:176-182
43. Steering Committee of the Physicians#x0027; Health Study Research Group. Final report of the aspirin component of the ongoing Physicians#x0027; Health Study. N Engl J Med 1989; 321:129-135
44. Goldman S., Copeland J., Moritz T., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988; 77:1324-1332
45. Khazan U., Toth M., Mutgi A. Diclofenac sodium and bruising. Ann Intern Med 1990; 112:472-473
46. McIntyre B.A., Philip R.B., Inwood M.J. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Ther 1978; 24:616-621
47. Thomas P., Hepburn B., Kim H.C., Saidi P. Nonsteroidal anti-inflammatory drugs in the treatment of hemophilic arthropathy. Am J Hematol 1982: 12:131-137
48. Nishizawa E.E., Wynalda D.J. Inhibitory effect of ibuprofen (Motrin) on platelet function. Thromb Res 1981; 21:347-356
49. McClure P.D., Casserly J.G., Monsier C., Crazier D. Carbenicillin-induced bleeding disorder. Lancet 1970; 2:1307-1308
50. Brown C.H. III, Natelson E.A., Bradshaw M.W., Williams T.W. Jr., Alfrey C.P. Jr. The hemostatic defect produced by carbenicillin. N Engl J Med 1974; 291:265-270
51. Sattler F.R., Weitekamp M.R., Ballard J.O. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105:924-931
52. Haburchak D.R., Head D.R., Everett E.D. Postoperative hemorrhage associated with carbenicillin administration: report of two cases and review of the literature. Am J Surg 1977; 134:630-634
53. Somani P., Smith M.R., Gohara A., Kapila K. The effects of mezlocillin, ticarcillin and placebo on blood coagulation and bleeding time in normal volunteers. J Antimicrob Chemother 1983; 11:Suppl C:33-41.
54. Fass R.J., Copelan E.A., Brandt M.L., Moeschberger M.L., Ashton J.J. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis 1987; 155:1242-1248
55. Gentry L.O., Jemsek J.G., Natelson E.A. Effects of sodium piperacillin on platelet function in normal volunteers. Antimicrob Agents Chemother 1981; 19:532-533
56. Brown C.H. III, Natelson E.A., Bradshaw M.W., Alfrey C.P. Jr., Williams T.W. Jr. Studies of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother 1975; 7:652-657
57. Gentry L.O., Wood B.A., Natelson E.A. Effects of apalcillin on platelet function in normal volunteers. Antimicrob Agents Chemother 1985; 27:683-684
58. Brown C.H. III, Bradshaw M.W., Natelson E.A., Alfrey C.P. Jr., Williams T.W. Jr. Defective platelet function following the administration of penicillin compounds. Blood 1976; 47:949-956
59. Andrassy K.E., Scherz M., Ritz B., et al. Penicillin-induced coagulation disorder. Lancet 1976; 2:1039-1041
60. Ikeda Y., Kikuchi M., Matsuda S., et al. Inhibition of platelet function by sulbenicillin and its metabolite. Antimicrob Agents Chemother 1978; 13:881-883
61. Dijkmans B.A.C., van der Meer J.W.M., Boekhout-Mussert M.J., Zaal de Jong M., Mattie H. Prolonged bleeding time during azlocillin therapy. J Antimicrob Chemother 1980; 6:554-556
62. Alexander D.P., Russo M.E., Fohrman D.E., Rothstein G. Nafcillin-induced platelet dysfunction and bleeding. Antimicrob Agents Chemother 1983; 23:59-62.
63. Natelson E.A., Brown C.H. III, Bradshaw M.W., Alfrey C.P. Jr., Williams T.W. Jr. Influence of cephalosporin antibiotics on blood coagulation and platelet function. Antimicrob Agents Chemother 1976; 9:91-93
64. Brown R.B., Klar J., Lemeshow S., Teres D., Pestides H., Sands M. Enhanced bleeding with cefoxitin or moxolactam: statistical analysis within a defined population. Arch Intern Med 1986; 146:2159-2164
65. FitzGerald G.A. Dipyridamole. N Engl J Med 1987; 316:1247-1257
66. Cremer K.F., Pieper J.A., Joyal M., Mehta J. Effects of diltiazem, dipyridamole, and their combination on hemostasis. Clin Pharmacol Ther 1984; 36:641-644
67. De Caterina R., Giannessi D., Crea F., et al. Inhibition of platelet function by injectable isosorbide dinitrate. Am J Cardiol 1984; 53:1683-1687
68. De Caterina R., Lombardi M., Bernini W., et al. Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. Am Heart J 1990: 119:855-862
69. Juvela S., Kaste M., Hillbom M. Effect of nimodipine on platelet function in patients with subarachnoid hemorrhage. Stroke 1990; 21:1283-1288
70. Weksler B., Gillick M., Pink J. Effect of propranolol on platelet function. Blood 1977; 49:185-196
71. Saxon A., Kattlove H. Platelet inhibition by nitroprusside, a smooth muscle inhibitor. Blood 1976; 47:957-961
72. Ikeda Y., Kikuchi M., Toyama K., Watanabe K., Ando Y. Inhibition of human platelet function by verapamil. Thromb Haemost 1981; 45:158-161
73. Dale J., Landmark K.H., Myhre E. The effects of nifedipine, a calcium antagonist, on platelet function. Am Heart J 1983; 105:103-105
74. Schafer A.I., Alexander R.W., Handin R.I. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55:649-654
75. Ring T., Knudsen F., Kristensen S.D., Larsen C.E. Nitroglycerin prolongs the bleeding time in healthy males. Thromb Res 1983; 29:553-559
76. Lawson D., Mehta J., Mehta P., Lipman B.C., Imperi G.A. Cumulative effects of quinidine and aspirin on bleeding time and platelet alpha-2-adrenoreceptors: potential mechanism of bleeding diathesis in patients receiving this combination. J Lab Clin Med 1986; 108:581-586
77. Green D., Ts#x0027;ao C.-H., Cerullo L., Cohen I., Ruo T.I., Atkinson A.J. Jr. Clinical and laboratory investigation of the effects of ε-aminocaproic acid on hemostasis. J Lab Clin Med 1985; 105:321-327
78. Lindblad B., Wakeheld T.W., Whitehouse W.M. Jr., Stanley J.C. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988; 22:55-59
79. Gimple L.W., Gold H.K., Leinbach R.C., et al. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 80:581-588
80. Mills D.C.B., Roberts G.C.K. Membrane active drugs and the aggregation of human blood platelets. Nature 1967; 213:35-38
81. Jain M.F., Eskow E., Kuchibhotla J., Colman R.W. Correlation of inhibition of platelet aggregation by phenothiazines and local anesthetics with their effects on a phospholipid bilayer. Thromb Res 1978; 13:1067-1075
82. Gilani A.H., Saeed S.A. A comparative study of the effects of local anaesthetics on platelet aggregation. Biochem Soc Trans 1990; 18:288-289
83. Aldort L.M., Niemetz J. Dissociation of platelet aggregation from clot retraction, potassium loss and adenosine triphosphatase activity. Proc Soc Exp Biol Med 1968; 128:658-661
84. Dalsgaard-Nielsen J., Risbo A., Simmelkjaer P., Gormsen J. Impaired platelet aggregation and increased bleeding time during general anesthesia with halothane. Br J Anaesth 1981; 53:1039-1042
85. Puszkin E., Gutfreund D., Aledort L.M. Hemostatic abnormalities in heroin addicts. Transfusion 1972; 12:9-11.
86. Shapiro R.S., Gerrard J.M., Ramsay N.K., et al. Selective deficiency in collagen-induced platelet aggregation during L-asparaginase therapy. Am J Pediatr Hematol Oncol 1980; 2:207-212
87. Panella T.J., Peters W., White J.G., Hannun Y.A., Greenberg C.S. Platelets acquire a secretion defect after high-dose chemotherapy. Cancer 1990; 65:1711-1716
88. Steinherz P.G., Miller D.R., Hilgartner M.W., Schmalzer E.A. Platelet dysfunction in vincristine treated patients. Br J Haematol 1976; 32:439-450
89. McKenna R., Ahmad T., Ts#x0027;ao C.-H., Frischer H. Glutathione reductase deficiency and platelet dysfunction induced by 1,3-bis(2-chlorethyl)-1-nitrosourea. J Lab Clin Med 1983; 102:102-115
90. Pogliani E.M., Fantasia R., Lambertenghi-Deliliers G., Cofrancesco E. Daunorubicin and platelet function. Thromb Haemost 1981; 45:38-42.
91. Ahr D.J., Scialla S.J., Kimbali D.B. Jr. Acquired platelet dysfunction following mithramycin therapy. Cancer 1978; 41:448-454
92. Thomson C., Forbes C.D., Prentice C.R.M. A comparison of the effects of antihistamines on platelet function. Thromb Diath Haemorrh 1973; 30:547-556
93. Rao A.K., Rao V.M., Willis J., Beckett C., Steiner R.M. Inhibition of platelet function by contrast media: iopamidol and ioxaglate versus iothalamate: work in progress. Radiology 1985; 156:311-313
94. Parvez Z., Moneada R., Fareed J., Messmore H.L. Antiplatelet action of intravascular contrast media: implications in diagnostic procedures. Invest Radiol 1984; 19:208-211
95. Zir L.M., Carvalho A.C., Harthorne J.W., Colman R.W., Lees R.S. Effect of contrast agents on platelet aggregation and 14C-serotonin release. N Engl J Med 1974; 291:134-135
96. Gafter U., Creter D., Zevin D., Catz R., Djaldetti M. Inhibition of platelet aggregation by contrast media. Radiology 1979; 132:341-342
97. Carvalho A.C.A., Colman R.W., Lees R.S. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation 1974; 50:570-574
98. The PACK Trial Group. Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis: a multi-center, double-blind, placebo-controlled trial. Thromb Res 1989; 55:13-23.
99. Langdell R.D., Adelson E., Furth F.W., Crosby W.H. Dextran and prolonged bleeding time: results of a sixty-gram, one-liter infusion given to one hundred sixty-three normal human subjects. JAMA 1958; 166:346-351
100. Weiss H.J. The effect of clinical dextran on platelet aggregation, adhesion, and ADP release in man: in vivo and in vitro studies. J Lab Clin Med 1967; 69:37-46.
101. Data J.L., Molony B.A., Meinzinger M.M., Gorman R.R. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3′:5′-cyclic monophosphate levels. Circulation 1981; 64:4-12.
102. Rossi E.C., Levin N.W. Inhibition of primary ADP-induced platelet aggregation in normal subjects after the administration of nitrofurantoin (Furadantin). J Clin Invest 1973; 52:2457-2467
103. Fisher C.A., Kappa J.R., Sinha A.K., Cottrell E.D., Reiser H.J., Addonizio V.P. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function. J Lab Clin Med 1987; 109:184-190
104. Di Minno G., Cerbone A.M., Mattioli P.L., Turco S., Iovine C., Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75:328-338
105. Hardisty R.M., Powling M.J., Nokes T.J.C. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990; 64:150-155
106. Dorso C.R., Levin R.I., Eldor A., Jaffe E.A., Weksler B.B. Chinese food and platelets. N Engl J Med 1980; 303:756-757
107. Srivastava K.C., Mustafa T. Spices: antiplatelet activity and prostanoid metabolism. Prostaglandins Leuko Essent Fatty Acids 1989; 38:255-266
108. Makheja A.N., Bailey J.M. Antiplatelet constituents of garlic and onion. Agents Actions 1990; 29:360-363
109. Sarji K.E., Kleinfelder J., Brewington P., Gonzalez J., Hempling H., Colwell J.A. Decreased platelet vitamin C in diabetes mellitus: possible role in hyperaggregation. Thromb Res 1979; 15:639-650
110. Stuart M.J., Oski F.A. Vitamin E and platelet function. Am J Pediatr Hematol Oncol 1979; 1:77-82.
111. Srivastava K.C. Extracts from two frequently consumed spices — cumin (Cuminum cyminum) and turmeric (Curcuma longa) — inhibit platelet aggregation and alter eicosanoid biosynthesis in human blood platelets. Prostaglandins Leuko Essent Fatty Acids 1989; 37:57-64.
112. Deykin D., Janson P., McMahon L. Ethanol potentiation of aspirin-induced prolongation of the bleeding time. N Engl J Med 1982; 306:852-854
113. Haut M.J., Cowan D.H. The effect of ethanol on hemostatic properties of human blood platelets. Am J Med 1974; 56:22-33.
114. Goodnight S.H. Jr., Harris W.S., Connor W.E. The effect of ω-3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981; 58:880-885
115. von Schacky C., Weber P.C. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76:2446-2450
116. Hammerschmidt D.E. Szechwan purpura. N Engl J Med 1980; 302:1191-1193
117. Rose K.D., Croissant P.D., Parliament C.F., Levin M.B. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurg 1990; 26:880-882
118. George J.N., Shattil S.J. Acquired disorders of platelet function. In: Hoffman R, Benz EJ, Cohen HJ, Furie B, Shattil SJ, eds. Hematology: basic principles and practice. New York: Churchill Livingstone. 1990: 1528-46.
119. Leist E.R., Banwell J.G. Products containing aspirin. N Engl J Med 1974; 291:710-712
120. Flower R.J., Moneada S., Vane J.R. Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: Oilman AG, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman#x0027;s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 674-715.
121. Arrowsmith J.B., Kennedy D.L., Kuritsky J.N., Faich G.A. National patterns of aspirin use and Reye syndrome reporting. United States, 1980 to 1985. Pediatrics 1987; 79:858-863
122. Ferraris V.A., Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 1983; 156:439-442
123. Roth G.J., Siok C.J. Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 1978; 253:3782-3784
124. Weksler B.B., Pett S.B., Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308:800-805
125. Kallmann R., Nieuwenhuis H.K., de Groot P.G., van Gijn J., Sixma J.J. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1α excretion in healthy subjects. Thromb Res 1987; 45:355-361
126. Mielke C.H. Jr. Influence of aspirin on platelets and the bleeding time. Am J Med 1983; 74:Suppl 6A:72-78
127. Kaneshiro M.M., Mielke C.H. Jr., Kasper C.K., Rapaport S.I. Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med 1969; 281: 1039-42.
128. Gaspari F., Vigano G., Orisio S., Bonati M., Livio M., Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79:1788-1797
129. Chesebro J.H., Fuster V., Elveback L.R., et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared to dipyridamole. Am J Cardiol 1983:51:1537-1541
130. Bick R.L. Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost 1976; 3:59-82.
131. Torosian M., Michelson E.L., Morganroth J., MacVaugh H. III. Aspirin- and coumadin-related bleeding after coronary artery bypass graft surgery. Ann Intern Med 1978; 89:325-328
132. Michelson E.L., Morganroth J., Torosian M., MacVaugh H. III. Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 1978; 76:694-697
133. Taggart D.P., Siddiqui A., Wheatley D.J. Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements. Ann Thorac Surg 1990; 50:424-428
134. Ferraris V.A., Ferraris S.P., Lough F.C., Berry W.R. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg 1988; 45:71-74
135. Rajah S.M., Salter M.C.P., Donaldson D.R., et al. Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts: a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg 1985; 90:373-377
136. Karwande S.V., Weksler B.B., Gay W.A. Jr., Subramanian V.A. Effect of preoperative antiplatelet drugs on vascular prostacyclin synthesis. Ann Thorac Surg 1987; 43:318-322
137. Harris W.H., Salzman E.W., Athanasoulis C.A., Waltman A.C., De Sanctis R.W. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977; 297:1246-1249
138. Amrein P.C., Ellman L., Harris W.H. Aspirin-induced prolongation of the bleeding time and perioperative blood loss. JAMA 1981; 245:1825-1828
139. Kitchen L., Erichson R.B., Sideropoulos H. Effect of drug-induced platelet dysfunction on surgical bleeding. Am J Surg 1982; 143:215-217
140. Stuart M.J., Gross S.J., Elrad H., Graeber J.E. Effects of Acetylsalicylic Acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982; 307:909-912
141. Horlocker T.T., Wedel D.J., Offord K.P. Does preoperative antiplatelet therapy increase the risk of hemorrhagic complications associated with regional anesthesia? Anesth Analg 1990; 70:631-634
142. Shattil S.J., Bennett J.S., McDonough M., Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 1980; 65:329-337
143. Burroughs S.F., Johnson G.J. ß-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin. Blood 1990; 75:1473-1480
144. Wislff F., Godal H.C. Prolonged bleeding time with adequate platelet count in hospital patients. Scand J Haematol 1981; 27:45-50.
145. Lipsky J.J. Antibiotic-associated hypoprothrombinaemia. J Antimicrob Chemother 1988; 21:281-300.
146. Gruber U.F., Duckert F., Fridrich R., Torhorst J., Rem J. Prevention of postoperative thromboembolism by Dextran 40, low doses of heparin, or xantinol nicotinate. Lancet 1977; 1:207-210
147. Kline A., Hughes L.E., Campbell H., Williams A., Zlosnick J., Leach K.G. Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized double-blind trial. BMJ 1975; 2:109-112
148. Ware J.A., Clark B.A., Smith M., Salzman E.W. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 1989; 73:172-176
149. Remuzzi G., Benigni A., Dodesini P., et al. Reduced platelet thromboxane formation in uremia: evidence for a functional cyclooxygenase defect. J Clin Invest 1983; 71:762-768
150. Di Minno G., Cerbone A., Usberti M., et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 1986; 108:246-252
151. Steiner R.W., Coggins C., Carvalho A.C.A. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7:107-117
152. Stewart J.H., Castaldi P.A. Uraemic bleeding: a reversible platelet defect corrected by dialysis. Q J Med 1967; 36:409-423
153. Nenci G.G., Berrettini M., Agnelli G., Parise P., Buoncristiani U., Ballatori E. Effect of peritoneal dialysis, hemodialysis, and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine Nephron 1979; 23:287-292
154. Hutton R.A., O#x0027;Shea M.J. Haemostatic mechanism in uraemia. J Clin Pathol 1968; 21:406-411
155. Escolar G., Cases A., Bastida E., et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb–IIIa. Blood 1990; 76:1336-1340
156. Gordge M.P., Faint R.W., Rylance P.B., Neild G.H. Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 1988; 60:83-87
157. Livio M., Gotti E., Marchesi D., Mecca G., Remuzzi G., de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2:1013-1015
158. Fernandez F., Goudable C., Sie P., et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59:139-148
159. Moia M., Mannucci P.M., Vizzotto L., Casati S., Cattaneo M., Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2:1227-1229
160. van Geet C., Hauglustainc D., Verresen L., Vanrusselt M., Vermylen J. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989; 61:117-121
161. Kleinknecht D., Jungers P., Chanard J., Barbanel C., Ganeval D. Uremic and non-uremic complications in acute renal failure: evaluation of early and frequent dialysis on prognosis. Kidney Int 1972; 1:190-196
162. Zuckerman G.R., Cornette G.L., Clouse R.E., Harter H.R. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1985; 102:588-592
163. Ball W.G., Evans G. Diseases of the kidney. Philadelphia: P. Blakiston#x0027;s Sons, 1932: 250-3.
164. Hamberger J., Richet G., Crosnier J., et al. Nephrology. Philadelphia: W.B. Saunders, 1968: 347.
165. Relman A.S. Clinical aspects of chronic glomerulonephritis. In: Strauss MB, Welt LG, eds. Diseases of the kidney. Boston: Little, Brown. 1963: 320-34.
166. Kirkman R.L., Strom T.B., Weir M.R., Tilney N.L. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34:347-351
167. Morrison G., Geheb M.A., Earley L.E. Chronic renal failure. In: Seidin DW, Giebisch G, eds. The kidney: physiology and pathophysiology. New York: Raven Press. 1985: 1901-43.
168. Hakim R.M., Lazarus J.M. Medical aspects of hemodialysis. In: Brenner BM, Rector FC Jr, eds. The kidney. Philadelphia: W.B. Saunders. 1986: 1791-845.
169. Diaz-Buxo J.A., Donadio J.V. Jr. Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin Nephrol 1975; 4:223-227
170. Schreiner G.F. The nephrotic syndrome. In: Strauss MB, Welt LG, eds. Diseases of the kidney. Boston: Little, Brown, 1963: 335-444.
171. Ciba Foundation Symposium. Renal biopsy. Boston: Little, Brown, 1961: 371-3.
172. Buerling-Harbury C., Galvan C.A. Acquired decrease in platelet secretory ADP associated with increased post-operative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978; 52:13-23.
173. Harker L.A., Malpass T.W., Branson H.E., Hessel E.A. II, Slichter S.J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alphagranule release. Blood 1980; 56:824-834
174. Files J.C., Malpass T.W., Yee E.K., Ritchie J.L., Harker L.A. Studies of human platelet alpha-granule release in vivo. Blood 1981; 58:607-618
175. Holloway D.S., Summaria L., Sandesara J., Vagher J.P., Alexander J.C., Caprini J.A. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59:62-67
176. George J.N., Pickett E.B., Saucerman S., et al. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78:340-348
177. Abrams C.S., Ellison N., Budzynski A.Z., Shattil S.J. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75:128-138
178. Salzman E.W., Weinstein M.J., Weintraub R.M., et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. N Engl J Med 1986; 314:1402-1406
179. Hackmann T., Gascoyne R.D., Naiman S.C., et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989; 321:1437-1443
180. Pareti F.I., Capitanio A., Mannucci L., Ponticelli C., Mannucci P.M. Acquired dysfunction due to the circulation of “exhausted” platelets. Am J Med 1980; 69:235-240
181. Stoff J.S., Stemerman M., Steer M., Salzman E., Brown R.S. A defect in platelet aggregation in Banter#x0027;s syndrome. Am J Med 1980; 68:171-180
182. Lim S.H., Tan C.E., Agasthian T., Chew L.S. Acquired platelet dysfunction with eosinophilia: review of seven adult cases. J Clin Pathol 1989; 42:950-952
183. Szczeklik A., Milner P.C., Birch J., Watkins J., Martin J.F. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. Thromb Haemost 1986; 56:283-287
184. Carvalho A.C.A., Quinn D.A., DeMarinis S.M., Beitz J.G., Zapol W.M. Platelet function in acute respiratory failure. Am J Hematol 1987; 25:377-388
185. Bracey A.W., Wu A.H.B., Aceves J., Chow T., Carlile S., Hoots W.K. Platelet dysfunction associated with Wilms tumor and hyaluronic acid. Am J Hematol 1987; 24:247-257
186. Heyns A.D., Fraser J., Retief F.P. Platelet aggregation in chronic idiopathic thrombocytopenic purpura. J Clin Pathol 1978; 31:1239-1243
187. Dorsch C.A., Meyerhoff J. Mechanisms of abnormal platelet aggregation in systemic lupus erythematosus. Arthritis Rheum 1982; 25:966-973
188. Weiss H.J., Rosove M.H., Lages B.A., Kaplan K.L. Acquired storage pool deficiency with increased platelet-associated IgG. Am J Med 1980; 69: 711-7.
189. Stuart M.J., Kelton J.G., Allen J.B. Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. Blood 1981; 58:326-329
190. Nieuwenhuis H.K., Zwaginga J.J., Sixma J.J. Analysis of patients with a prolonged bleeding time. Thromb Haemost 1987; 58:527. abstract.
191. Niessner H., Clemetson K.J., Panzer S., Mueller-Eckhardt C., Santoso S., Bettelheim P. Acquired thrombasthenia due to GP IIb-IIIa-specific autoantibodies. Blood 1986; 68:571-576
192. Kubota T., Tanoue K., Murohashi I., et al. Autoantibody against platelet glycoprotein IIb–IIIa in a patient with non-Hodgkin#x0027;s lymphoma. Thromb Res 1989; 53:379-386
193. Devine D.V., Currie M.S., Rosse W.F., Greenberg C.S. Pseudo-Bemard-Soulier syndrome: thrombocytopenia caused by autoantibody to platelet glycoprotein Ib. Blood 1987; 70:428-431
194. Deckmyn H., Chew S.L., Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost 1990; 64:74-79
195. Schafer A.I. Bleeding and thrombosis in the myeloproliterative disorders. Blood 1984; 64:1-12.
196. Berndt M.C., Kabral A., Grimsley P., Watson N., Robertson T.I., Bradstock K.F. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 1988; 68:97-101.
197. Kessler C.M., Klein H.G., Havlik R.J. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982; 50:157-167
198. Murphy S., Davis J.L., Walsh P.N., Gardner F.H. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med 1978; 138:1251-1253
199. Cowan D.H., Graham R.R. Jr., Baunach D. The platelet defect in leukemia: platelet ultrastructure, adenine nucleotide metabolism, and the release reaction. J Clin Invest 1975; 56:188-200.
200. Meschengieser S., Blanco A., Maugeri N., et al. Platelet function and intraplatelet von Willebrand factor antigen and fibrinogen in myelodysplastic syndromes. Thromb Res 1987; 46:601-606
201. Rosove M.H., Naeim F., Harwig S., Zighelboim J. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood 1980; 55:903-906
202. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol 1973; 10:125-133
203. Vigliano E.M., Horowitz H.I. Bleeding syndrome in a patient with IgA myeloma: interaction of protein and connective tissue. Blood 1967; 29:823-836
204. DiMinno G., Coraggio F., Cerbone A.M., et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77:157-164
205. Roussi J.H., Houbouyan L.L., Alterescu R., Franc B., Goguel A.F. Acquired Von Willebrand#x0027;s syndrome associated with hairy cell leukemia. Br J Haematol 1980; 46:503-506
206. Mohri H., Noguchi T., Kodama F., Itoh A., Ohkubo T. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987; 87:663-668
207. Juhl A. DDAVP, cryoprecipitate, and highly “purified” factor VIII concentrate in uremia. Nephron 1986; 43:305-306
208. Bolan C.D., Alving B.M. Pharmacologic agents in the management of bleeding disorders. Transfusion 1990; 30:541-551
209. Mannucci P.M., Remuzzi G., Pusineri F., et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308:8-12.
210. DiMichele D.M., Hathaway W.E. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33:39-45.
211. Weinstein R.E., Bona R.D., Altman A.J., et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 1989; 32:258-261
212. Smith T.J., Gill J.C., Ambruso D.R., Hathaway W.E. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31:199-202.
213. Desmopressin and arterial thrombosis. Lancet 1989; 1:938-939
214. Shepherd L.L., Hutchinson R.J., Worden E.K., Koopman C.F., Coran A. Hyponatremia and seizures after intiavenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114:470-472
215. Rapaport S.I. Preoperative hemostatic evaluation: which tests, if any? Blood 1983; 61:229-231